First author Hamilton Oh, now at Icahn School of Medicine at Mt. Sinai, New York, and colleagues identified these potential markers during a proteomics analysis of CSF from 3,397 participants in six ...

Roche's trontinemab data showed dose-dependent amyloid reduction in Alzheimer's patients, while its Elecsys pTau181 test aims ...

Insoluble tau aggregates, particularly neurofibrillary tangles, play a crucial role in the pathology of Alzheimer’s disease. These aggregates correlate closely with the clinical symptoms of the ...

Genentech announced that new data were presented at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s ...

The assays measure phosphorylated tau 181 and apolipoprotein 4 to rule out whether a patient has Alzheimer's disease.

Roche presented new data at the AD/PD 2025 International Conference demonstrating that trontinemab, in its Phase Ib/IIa Brainshuttle™ AD study, ...

Swiss pharma giant Roche’s Genentech subsidiary has presented new data at the AD/PD 2025 International Conference on ...

New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle™ AD study – ...

Researchers have developed a blood test based on a protein biomarker for tau tangles that can help diagnose Alzheimer’s ...

There's still so much we don't know about Alzheimer's disease, but the link between poor sleep and worsening disease is one ...

Weight loss drugs such as semaglutide, found in Ozempic and Wegovy, are tied to a 40% reduced risk of an Alzheimer's disease ...

Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.